Molecular Breast Marker

Michael T. Nelson, M.D.
University of Minnesota
Department of Radiology
Introduction

• There is a need for a universal Breast Marker that can be seen easily on mammography, ultrasound, and MRI imaging. Multiple FDA approved soft tissue markers are available to radiologists and surgeons, but all markers do not work for several marking needs.

• The development of a new breast marker (BiomarC, Carbon Medical Technologies) with distinctive characteristics on digital mammography, film screen mammography, ultrasound and MRI was tested on 27 patients with 32 markers placed after ultrasound and stereotactic biopsies.
Images were obtained on:

1. HTL 3000 Ultrasound
2. Senograph GE Digital Mammogram
3. Fischer Stereotactic Biopsy Unit
4. 1.5T Philips MRI with Philips dedicated breast coils
5. 4T images were obtained at CMRR on Oxford Magnet with Varian Console
6. Spectroscopy was obtained using laser technique on 1.5T and 4T Magnets
7. Choline measurements were standardized and obtained on 1.5T and 4.0T magnets
Case 1

- 47-year old white female with palpable mass upper outer quadrant right breast
- Ultrasound core biopsy which showed invasive ductal carcinoma
- BiomarC placed under ultrasound
- Treatment: Lumpectomy and sentinel node and 1 micro metastasis in lymph node
4T-MRI

Choline peak is clearly visible over BiomarC

[tCho] = 7.63 mmol/kg water
1.5T MRI

BiomarC Placement
MRI 1.5T with Spectroscopy

Choline peak
Case 2

- 45-year-old white female with two areas of abnormal microcalcifications on screening mammogram right breast
- Stereotactic core biopsy showed carcinoma in situ and atypia
- Patient had prior stereotactic biopsy with carcinoma in situ in a third location
- All three areas were marked with unique breast markers
Case #2
US Images

Stereotactastic Images
Case #2
Stereotactic Marker Placement
Case #3

- 44-year old female with stereotactic biopsy of left breast with BiomarC placed
- 2nd lesion biopsied under ultrasound guidance with a SenoRx S-shaped clip placed
- Pathology showed both areas were FCC
Case #4

- 38-year old white female presented with existing IDC with outside biopsy
- Second lesion in lymph node was identified on ultrasound exam in the right breast
- BiomarC was placed in existing tumor under US guidance
- 2nd BiomarC was placed in second tumor under US guidance identified at 4 o’clock
- Lymph node in right axilla was biopsied and also positive for IDC. Lymph node not marked with marker
- Pathology showed two areas of IDC with positive lymph node in the right breast
Area 1 – IDC
Existing tumor

Area 2 – IDC
seen on US

BiomarC

Area 1 – IDC
Existing tumor

Area 2 – IDC
seen on US
BiomarC on CT within Breast IDC mass
No CT Artifact

BiomarC in Right Breast Mass

Second IDC Lesion in Right Breast Medially with BiomarC
PET Scan Showing Two Areas of IDC Right Breast and Positive Right Axillary Lymph Node - BiomarC Did Not Interfere With PET Scan

BiomarC in center of mass does not interfere with spectroscopy

Spectrum taken right over the RM with minimal error

\[ [t_{\text{Cho}}] = 4.85 \pm 0.07 \]
Case #5

• 43-year old white female has two sisters with breast cancer
• Had screening MRI with one area of increased gadolinium enhancement
• 2 BiomarC markers were placed at the site of enhancement and an open biopsy was done with wire localization
• Biopsy showed FCC
Case #5

7 cm Kopans wire localization done with Digital Mammography using BiomarC markers placed under MRI
Case #5

2 BiomarC markers placed under MRI Guidance with Titanium 120 mm Trochar
Case #6

• 32-year old white female with palpable mass left breast
• US showed hypoechoic mass at 11:30 o’clock 3cm from nipple
• US Bx completed with BiomarC placed under US guidance
• Pathology showed benign fibrocystic changes
• BiomarC placed under US guidance and was well visualized on US and mammography
Case #6

BiomarC placed under US guidance with good visualization
Case #6

BiomarC markers under Digital mammography
Case #7

• 50-year old white female with two areas of abnormal microcalcifications in right breast on screening mammogram

• Both areas were biopsied using stereotactic vacuum assisted 11-gauge biopsy needle

• Superior area was marked with BiomarC using wet technique through hollow catheter

• 2\textsuperscript{nd} biopsy area was marked with a new SenoRx titanium marker

• Pathology both areas was FCC
Case #7

- Neither BiomarC or SenoRx titanium clip could be seen on US after stereotactic placement

- Both clips were placed in fatty breast tissue
Case #7

Stereotactic Placement of BiomarC seen under Stereotactic Imaging (Fischer Imaging Biopsy Table)
Case #7

BiomarC markers

SenoRx markers
Case #7

BiomarC

SenoRx Titanium
Case #8

- 39-year old white female with palpable lump right breast at 12 o’clock
- US core Bx 14-gauge was done with placement of BiomarC under ultrasound guidance
- Digital mammography showed marker to be in good position
- US taken 7-days later showed the BiomarC well visualized under US
- Pathology showed IDC
BiomarC placed under US Guidance

Good visualization of BiomarC 7-days after placement under US
Case #8

BiomarC
Case # 9

- 19-year old black female with bilateral palpable masses
- Bilateral US biopsies with bilateral BiomarC placement within masses
- Pathology showed bilateral fibroadenomas
- Patient has multiple fibroadenomas and therefore BiomarC was placed to identify mass which was biopsied in each breasts
Case #9

Left Breast Fibroadenoma
Case #9
BiomarC 7 days after biopsy

Right Breast Fibroadenoma
Case #9

Right CC with BiomarC

Left CC with BiomarC
Case #9

Right MLO with BiomarC

Left MLO with BiomarC
Case #10

- 64-year old white female with left breast mass
- US core Bx at 3 o’clock 6 cm from nipple
- BiomarC breast marker was placed under US guidance
- Pathology showed IDC
Case #10

Digital Mammo with BiomarC
Case # 11

• 48-year old female with palpable mass in left breast at 2 o’clock
• US biopsy was completed of left breast mass and left axillary lymph node
• 2 BiomarC breast markers were placed: one in the mass and one in the left axillary lymph node
• Pathology was IDC with positive lymph node
BiomarC in IDC mass

BiomarC placed in malignant lymph node in left axilla
Case #11

BiomarC in IDC

BiomarC in lymph node

BiomarC in IDC
Results

- BiomarC has a distinctive barbell shape that is not confused with existing calcifications within the breast tissue
- BiomarC was easily placed under stereotactic guidance thru an existing 11-gauge Bx needle using a hollow side beveled plastic catheter
- BiomarC was placed under US guidance. The delivery system was well-visualized under ultrasound guidance and BiomarC was well visualized during placement
- BiomarC was seen on CT scanning of the breast and caused no artifact on cross-sectional imaging
Results-Continued

• BiomarC did not interfere with macro-molecular imaging on high field MRI T4 and 1.5T breast imaging. BiomarC also did not interfere with PET or fusion scanning

• BiomarC was placed using MRI guidance in magnetic field using a Philips 1.5T breast grid and Philips biopsy breast coils. Post-digital mammogram showed excellent placement of the BiomarC

• BiomarC can be seen at 7 and 21 days interval if it is placed within the lesion (dark background)

• BiomarC is not well visualized under ultrasound if the marker is not placed directly into the lesion. If the markers is placed in fibrocystic tissue or in fatty tissue the marker was not seen after deployment

• Follow-up digital and film screen mammography taken at 4-5 months on 4 patients showed no migration of the BiomarC (on benign biopsy cases)
Overall Impression of BiomarC

• It works as well or better than any other breast tissue marker tested in our facility.
• BiomarC does have one large advantage in the future:

“Macromolecular Imaging on Breast Abnormalities will be possible in the future if the abnormality is marked with BiomarC!”
References


References (Continued)


